康氏2号方联合甘利欣抗肝炎后肝纤维化的临床观察

目的 观察康氏2号方联合甘利欣抗肝炎后肝纤维化的临床疗效。方法 60例慢性乙型肝炎患者随机分为2组，对照组30例用甘利欣注射液150mg加10％葡萄糖注射液250ml静脉滴注，治疗组30例在对照组治疗基础上加用康氏2号方，每次1包（10g，每g含生药2.09g），1日2次口服。2组均3个月为1个疗程。2组病例均每2周查1次肝功能，每月查1次血清肝纤维化指标。结果 （1）治疗组在治疗后4项肝纤维化标有下降，有非常显著性差异（P＜0.01）；（2）对照组在治疗后4项肝纤维化指标有下降，其中层粘蛋白（LN）、透明质酸（HA）有非常显著性差异（P＜0.01），Ⅲ型前胶原（PCⅢ）、Ⅳ型肝原（CⅣ）有显著性差异（P＜0.05）；（3）治疗后治疗组与对照组4项肝纤维化指标比较，HA、PCⅢ、CⅣ有显著性差异（P＜0.05），LN有非常显著性差异（P＜0.01）；（4）治疗组的肝功能复常时间比对照组早，2组有显著性差异（P＜0.05）。结论 康氏2号方联合甘利欣注射液具有明显的抗肝炎后肝纤维化的作用，并在改善肝功能方面有协同作用。

An observation of the effect of hepatic fibrosis fron chronic hepatitis treated with improvement perception of Kangshi combined with Ganlixin injection

Objective To observe the effect of hepatic fibrosis from chronic hepatitis treated with improvement perception of Kangshi combined with Ganlixin injection. Methods 60 cases of hepatic fibrosis from chronic hepatitis were randomly allocated to two groups. In control group ( n =30) only Ganlixin injection was used, and in treatment group ( n =30) Combination of Ganlixin injection and improvement perception of Kangshi was carried on, with a course of three months in both groups. Results 4 markers of hepatic fibrosis after treatment in treatment group was obviously lower than those in control group after treatment ( P < 0.05, or 0.01), at same time there were significant differences in 4 markers of hepatic fibrosis between before and after treatment in both groups. Recovery duration of liver function in treatment group ( 6.4286 +- 2.897 ) was shorter than that in control group (8.1667 +- 3.0598, P < 0.05). Conclusion Therapy of improvement perception of Kangshi combined with Ganlixin injection plays a role on the treatment of hepatic fibrosis from chronic hepatitis.